Gold, M. Et Al. 2024. Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the ruby trial. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , no.SUPPL_3 .

Gold, M., Bolling, M. F., Sharma, S., Kommoss, S., Gilbert, L., Ring, K., ... Reyners, A.(2024). Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the ruby trial. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , no.SUPPL_3.

Gold, Michael Et Al. "Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the ruby trial," INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , no.SUPPL_3, 2024

Gold, Michael Et Al. "Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the ruby trial." INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , no.SUPPL_3, 2024

Gold, M. Et Al. (2024) . "Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the ruby trial." INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER , no.SUPPL_3.

@article{article, author={Michael Gold Et Al. }, title={Efficacy and safety of dostarlimab plus chemotherapy in patients with endometrial cancer by age category in part 1 of the ruby trial}, journal={INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER}, year=2024}